Total medical devices industry private equity deals in Q1 2019 worth $1.5bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 31.2% over the previous quarter and a drop of 48.5% when compared with the last four-quarter average, which stood at $2.91bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.01bn. At the country level, the US topped the list in terms of deal value at $1.01bn.
In terms of volumes, Europe emerged as the top region for medical devices industry private equity deals globally, followed by North America and then Middle East and Africa.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The top country in terms of private equity deals activity in Q1 2019 was the US with nine deals, followed by France with four and The Netherlands with three.
In 2019, as of the end of Q1 2019, medical devices private equity deals worth $1.5bn were announced globally, marking a decrease of 66.4% year on year.
Medical devices industry private equity deals in Q1 2019: Top deals
The top five medical devices industry private equity deals accounted for 96.4% of the overall value during Q1 2019.
The combined value of the top five medical devices industry private equity deals stood at $1.45bn, against the overall value of $1.5bn recorded for the quarter. The top announced medical devices industry private equity deal tracked by GlobalData in Q1 2019 was Ontario Teachers’ Pension Plan and Silver Lake Partners’ $1bn private equity deal with Verily Life Sciences.
In second place was the $339.05m private equity deal with Dutch Ophthalmic Research Center International by Eurazeo and in third place was Alychlo, Balderton Capital, Generation Investment Management Services and IDInvest Partners’ $77m private equity deal with Sophia Genetics.
The $18.1m private equity deal with Evolucare Group by Essling Capital and Alpha Capital Anstalt, Deerfield Management, MORE Investment House, Triple Gate Capital and West Elk Partners’ private equity deal with Itamar Medical for $11.5m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.